Ripretinib
INTRIGUE
Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 453
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Ripretinib 150 mg | GIST after imatinib (ITT n = 226) | 150 mg | ITT | sunitinib 50 mg 4/2 | median progression-free survival (IRR), ITT: 8 months, primary analysisprogression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significantmedian progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysisobjective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P |
| Sunitinib 50 mg 4/2 | GIST after imatinib (ITT n = 227) | 50 mg | ITT | n/r | median progression-free survival (IRR), ITT: 8.3 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 7 months, primary analysisobjective response rate, KIT exon 11 ITT: 14.6%, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratorymedian PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory |